March 27, 2024
Tentative Program
10:00:10:20 | Enhanced bone healing under Immunomodulation |
George M. Weisz, University of New South Wales, Australia | |
10:20:10:40 | A potential therapeutic drug for osteoporosis: prospect for osteogenic LncRNAs |
Fanjin Meng, North Sichuan Medical College, China | |
10:40:11:00 | Development of an Intelligent Nomogram for Predicting Nonadherence to Biologic Treatment in Rheumatoid Arthritis Patients |
Zige Liu, The First Affiliated Hospital of Guangxi Medical University, China | |
11:00:11:20 | Tofacitinib versus Methotrexate as the First Line Disease-Modifying Antirheumatic Drugs in the Treatment of Rheumatoid Arthritis: an open-label random |
Mohammad Mamun Khan, Department of Rheumatology, Bangabandhu Sheikh Mujib Medical University, Bangladesh. | |
11:20:11:40 | Evolution of biomarker research in autoimmunity conditions for health professionals and clinical practice: antibody-proteases as trans-lational tools designed to monitor autoimmune diseases at Clinical and Subclinical Stages |
Sergey Suchkov, Precision Nutriciology & Biodesign of the Institute for Biotech & Global Health of RosBioTech, Russia | |
11:40:12:00 | Altered BTLA expression and function in lupus T cells: consequences for therapeutic targeting |
Fanny Monneaux, CNRS, Institut de Biologie Moléculaire et Cellulaire, Immunologie, Immunopathologie et Chimie Thérapeutique, Strasbourg, France | |
12:00:12:10 Networking Break |
|
12:10:12:30 | Relationship between different anti-rheumatic drug therapies and complementary and alternative medicine in patients with rheumatoid arthritis: an interview based cross-sectional study |
BEDOR A. ALOMARI, Department of Pharmaceutical Service, Prince Sultan Military Medical City, Riyadh, Saudi Arabia | |
12:30:12:50 | Current and novel immunotherapies for autoimmune disease with B-cell lineage targets: “B”-aware of secondary antibody deficiency |
Mohammed Yousuf Karim , Department of Pathology, Sidra Medicine, Doha, Qatar | |
12:50:13:10 | Functional Analysis of Autoantibody Signatures in Rheumatoid Arthritis |
Andreas Weinhäusel, AIT Austrian Institute of Technology GmbH, Austria | |
13:10:13:30 | Antibodies against phosphorylcholine and protection in rheumatic diseases and other chronic inflammatory conditions |
Johan Frostegård, IMM, Karolinska Institutet, Sweden | |
13:30:13:50 | MTADV 5-MER peptide suppresses lung fibrosis ,RA, IBD and MS mouse models and inhibits human fibroblasts biological functions by targeting SAA, which fuels fibrosis |
David Naor , The Lautenberg center of immunology and cancer research, faculty of medicine, Hebrew University of Jerusalem, Israel | |
13:50:14:10 | The role of hydrogen sulfide in the analgesic effects of delta-opioid receptors during osteoarthritis pain in mice |
Olga Pol, Autonomous University of Barcelona, Spain | |
14:10:14:20 Networking Break |
|
14:20:14:40 | A novel loss-of-function mutation in LACC1 underlies hereditary juvenile arthritis with extended intra-familial phenotypic heterogeneity |
Yonatan Butbul, Director of the Department of Pediatric Rheumatology and Pediatric Day Hospitalization at Rambam Hospital, Israel | |
14:40:15:00 | Treatment of Experimental Autoimmune Encephalomyelitis with an Inhibitor of Phosphodiesterase-8 (PDE8) |
Stefan Brocke, Immunology, UConn Health, USA | |
15:00:15:20 | Galactose-Deficient IgA1 B cells in the Circulation of IgA Nephropathy Patients Carry Preferentially Lambda Light Chains and Mucosal Homing Receptors |
Raska Milan, Dept. of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic | |
15:20:15:40 | Evidence for Bacterial Pathogenesis of Multiple Sclerosis in Humans |
John Kriesel, University of Utah School of Medicine, Department of Internal Medicine, USA | |
15:40:16:00 | Integrating digital inhalers into clinical care of patients with asthma and chronic obstructive pulmonary disease |
Rajan K. Merchant, Allergy, Asthma, and Clinical Immunology Specialist , WCMG/DHMF/CSHRI/CSH, USA |